560088-66-6

Basic information

• Product Name: [2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER
• Synonyms: [2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER
• CAS NO: 560088-66-6
• Molecular Formula: C₂₁H₂₅NO₅
• Molecular Weight: 371.4269
• Mol File: 560088-66-6.mol

Chemical Properties

• Boiling Point: 581.5°C at 760 mmHg
• Flash Point: 305.5°C
• Appearance: /
• Density: 1.208g/cm³
• Vapor Pressure: 2.3E-14mmHg at 25°C
• Refractive Index: 1.572
• CAS DataBase Reference: [2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER(560088-66-6)
• EPA Substance Registry System: [2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER(560088-66-6)

Safety Data

• Hazardous Substances Data: 560088-66-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER is used as a reagent in organic synthesis for the development of various pharmaceuticals and chemical compounds. Its unique molecular structure allows for the creation of a wide range of products with potential therapeutic applications.
Used in Research Industry:
In the research industry, [2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL]-CARBAMIC ACID 9H-FLUOREN-9-YLMETHYL ESTER serves as a building block for the production of various chemical compounds. Its versatility and unique properties make it a valuable asset in the field of organic chemistry, contributing to the advancement of scientific knowledge and the development of new technologies.

InChI:InChI=1/C21H25NO5/c23-10-12-26-14-13-25-11-9-22-21(24)27-15-20-18-7-3-1-5-16(18)17-6-2-4-8-19(17)20/h1-8,20,23H,9-15H2,(H,22,24)

Upstream product

• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 1321923-36-7 FmocNH-DEG-CH₂CONH-Gly-Phe-Leu-Gly-OBn 
• 1321923-37-8 FmocNH-DEG-CH₂CONH-Gly-Phe-Leu-Gly-OH 
• 1321923-38-9 FmocNH-DEG-CH₂CONH-Gly-Phe-Leu-Gly-EDADNS 
• 1321923-28-7 H₂N-DEG-CH₂CONH-Gly-Phe-Leu-Gly-EDADNS 
• 166108-71-0 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 

Relevant articles and documents

IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE

Provided herein is a conjugate for modulating a natural killer cell or myeloid cell, comprising a targeting moiety and an immunomodulating polynucleotide. Also provided herein is a pharmaceutical composition for modulating a natural killer cell or myeloid cell, comprising a conjugate comprising a targeting moiety and an immunomodulating polynucleotide, and a pharmaceutically acceptable excipient. Additionally provided herein are methods of their use for modulating a natural killer cell or myeloid cell and treating a proliferative disease.

IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE

Immunomodulating polynucleotides are disclosed. The immunomodulating polynucleotides may contain 5-modified uridine, 5-modified cytidine, a total of from 6 to 16 nucleotides, and/or one or more abasic spacers and/or internucleoside phosphotriesters. Also disclosed are conjugates containing a targeting moiety and one or more immunomodulating polynucleotides. The immunomodulating polynucleotides and conjugates may further contain one or more auxiliary moieties. Also disclosed are compositions containing the immunomodulating polynucleotides or the conjugates containing one or more stereochemically enriched internucleoside phosphorothioates. Further disclosed are pharmaceutical compositions containing the immunomodulating polynucleotides or the conjugates and methods of their use.

Hydrophilic and Cell-Penetrable Pyrrolidinyl Peptide Nucleic Acid via Post-synthetic Modification with Hydrophilic Side Chains

Peptide nucleic acid (PNA) is a nucleic acid mimic in which the deoxyribose-phosphate was replaced by a peptide-like backbone. The absence of negative charge in the PNA backbone leads to several unique behaviors including a stronger binding and salt independency of the PNA-DNA duplex stability. However, PNA possesses poor aqueous solubility and cannot directly penetrate cell membranes. These are major obstacles that limit in vivo applications of PNA. In previous strategies, the PNA can be conjugated to macromolecular carriers or modified with positively charged side chains such as guanidinium groups to improve the aqueous solubility and cell permeability. In general, a preformed modified PNA monomer was required. In this study, a new approach for post-synthetic modification of PNA backbone with one or more hydrophilic groups was proposed. The PNA used in this study was the conformationally constrained pyrrolidinyl PNA with prolyl-2-aminocyclopentanecarboxylic acid dipeptide backbone (acpcPNA) that shows several advantages over the conventional PNA. The aldehyde modifiers carrying different linkers (alkylene and oligo(ethylene glycol)) and end groups (-OH, -NH2, and guanidinium) were synthesized and attached to the backbone of modified acpcPNA by reductive alkylation. The hybrids between the modified acpcPNAs and DNA exhibited comparable or superior thermal stability with base-pairing specificity similar to those of unmodified acpcPNA. Moreover, the modified apcPNAs also showed the improvement of aqueous solubility (10-20 folds compared to unmodified PNA) and readily penetrate cell membranes without requiring any special delivery agents. This study not only demonstrates the practicality of the proposed post-synthetic modification approach for PNA modification, which could be readily applied to other systems, but also opens up opportunities for using pyrrolidinyl PNA in various applications such as intracellular RNA sensing, specific gene detection, and antisense and antigene therapy.

A convenient route to diversely substituted icosahedral closomer nanoscaffolds

The design and synthesis of icosahedral polyhedral borane closomer motifs based upon carbonate and carbamate anchoring groups for biomedical applications are described. Dodecacarbamate closomers containing easily accessible groups of interest at their linker termini were synthesized via activation of the B-OH vertices as aryl carbonates and their subsequent reaction with primary amines. Novel dodecacarbonate closomers were successfully synthesized for the first time by reacting [closo-B12(OH)12]2- with an excess of respective aryl chloroformates, utilizing relatively short reaction times, mild conditions and simple purification strategies, all of which had previously presented difficulties in closomer chemistry. This methodology for the 12-fold degenerate synthesis of carbonate and carbamate closomers will greatly facilitate further exploration of closomers as monodisperse nanomolecular delivery platforms.